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Abstract
Blocking tumor necrosis factor-α either with monoclonal antibodies
or with soluble receptor constructs has been proven to be effective
with an acceptable safety profile in patients with rheumatoid
arthritis, and more recently also in the diseases belonging to the
spondyloarthropathy concept. Nevertheless multiple questions still
remain unresolved especially concerning longer-term treatment.
Data from a recent manuscript by Baraliakos and colleagues seem
to indicate that at least for the vast majority of ankylosing
spondylitis patients treatment with infliximab can not be withdrawn,
if one wants to control disease activity in a continuous way.
Although still unproven, this might be of crucial importance with
regard to structure modification and prevention of ankylosis in this
chronic inflammatory disorder.
A few years ago, rheumatologists treating patients with
ankylosing spondylitis (AS) had to accept the fact that the
only goal of their proposed treatment was to alleviate pain
and stiffness. Disease modification, let alone ‘cure’ of the
disease, was an unrealistic endpoint. The advent of so-called
‘biological’ therapies at the end of the second millennium
provoked a therapeutic breakthrough seldom witnessed in
the field of rheumatology. Inhibition of tumor necrosis factor-α
(TNF-α) proved highly efficacious, with an acceptable safety
profile in the chronic treatment of rheumatoid arthritis. Not
only did the therapy turn out to alleviate signs and symptoms,
but it also improved greatly the quality of life of the patients,
and was shown to significantly retard the structural damage
that is typical of this chronic inflammatory disorder. In the field
of spondyloarthropathies (SpA), a group of diseases that
present rheumatologically mainly with spondylitis, pauci-
articular peripheral arthritis and enthesopathy, there is
conclusive short-term evidence for the efficacy of TNF-α
blockade, both with infliximab and etanercept. Nevertheless,
several questions remain with regard to the use of these
biological therapies in SpA.
First, long-term data on safety and efficacy of these
compounds are scarce. More specifically, for infliximab, which
has to be given by way of an intermittent intravenous
perfusion, we still have no definitive knowledge of the optimal
re-treatment strategy (dose and interval), especially with
regard to cost-effectiveness.
Second, almost no information is available on the optimal
duration of this type of treatment: should it be continued for
as long as the patient benefits from the treatment without
obvious side effects, or is there a time point after which
discontinuation can be safely considered? Should one stop
the therapy abruptly or is gradual tapering (either in dose or
re-treatment interval) more appropriate? Is ‘on-demand’
treatment safe and feasible; if so, what should the threshold
be before re-treatment can be considered?
Third, do these biological agents hold the promise of true
disease modification (meaning retardation or arrest of
progressive and irreversible structural damage) or is the
treatment merely blocking inflammation efficiently without
interfering with the underlying pathophysiological mechanisms
that for example lead to ankylosis in AS?
An interesting addition to our knowledge of TNF-α blockade
with infliximab in AS has been provided in a recent article by
Baraliakos and colleagues [1], who provide preliminary
answers to some of the questions raised above. The authors
followed a cohort of 42 AS patients who were initially treated
in a randomized placebo-controlled trial [2] and afterwards
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received open-label treatment with infliximab. All patients
were re-treated with infliximab at a dose of 5 mg/kg body
weight every 6 weeks. After completing the third year of
continuous treatment, patients gave consent to stop
infliximab treatment. They were followed regularly to monitor
closely a possible relapse of the disease, in which case they
were re-treated. From their experience we can deduce some
practical consequences.
Definitive cessation of anti-TNF-α treatment with infliximab was
not possible in this patient group. Relapse was observed in 41
of 42 cases: the mean time to relapse was 17.5 weeks.
However, re-treatment seemed to be safe and effective
(resulting in clinical improvement similar to the state before
withdrawal in all patients), giving the opportunity in selected
cases to interrupt the treatment. The authors also looked at
variables that might be able to predict a longer disease-free
interval. AS patients in partial remission as defined by the
Assessments in Ankylosing Spondylitis (ASAS) Working Group
criteria [3] had a mean time to relapse of 21.3 weeks, whereas
patients not in remission experienced on average a relapse after
15.4 weeks. Low levels of C-reactive protein at the time of
withdrawal were also associated with longer flare-free periods.
The present data indicate that, at least in most AS patients,
continuous treatment with infliximab, and probably also with
other TNF-α-blocking agents, remains necessary to control
signs and symptoms of this disease in a continuous manner.
It might be possible that this conclusion only holds true in the
case of long-standing disease and that there remains a
specific window of opportunity, probably at an early disease
stage, in which this type of immunomodulation might more
definitively influence the outcome of the disease. Specific
studies will be necessary to address this issue, but
undoubtedly this type of exercise will need to be preceded by
the development of a consistent case definition of ‘early
disease’. As long as AS is only classifiable when radiographic
sacroiliitis is present at least in stage 2 on both sides, it
seems obvious that at that moment irreversible damage has
been inflicted, and probably the immune system will have
reached a point of chronic stimulation that cannot be
switched off by merely blocking one cytokine.
Another interesting point is whether a continuous control of
signs and symptoms in the long term translates into true
disease modification or prevention of structural damage and
ankylosis. Although the data certainly cannot be extrapolated,
preliminary evidence suggests that continuous therapy with
non-steroidal anti-inflammatory drugs seems to be superior to
‘on-demand’ treatment in terms of retardation of radiographic
progression [4]. This brings us to another difficult question,
which is how to define ‘disease modification’ in AS. One
might look at this from three viewpoints: clinical data,
radiographic data (either conventional radiographs or newer
modalities), and finally data from the evaluation of target
tissues such as the synovial membrane.
From a clinical point of view, probably the best available tool
reflecting the potential to halt the disease is the evaluation of
the axial metrology. Classically, one evaluates the Bath
Ankylosing Spondylitis Metrology Index (BASMI) [5] or one of
its components. With regard to infliximab, clear improvements
in the BASMI have been observed in both open [6,7] and
placebo-controlled studies [2], although sometimes the
number of patients included in the subgroup of AS was too
low to reach statistical significance [8]. Alternatively, one
might evaluate the effect of a drug on the consequences of
ankylosis and/or destruction by looking at the improvement of
a functional index (BASFI) [9], with the caveat, of course, that
function is probably only well correlated with structural
damage in the later stages of the disease, whereas in the first
years inflammation might be the driving force. Invariably, a
major improvement in the BASFI has been reported in all
studies with infliximab.
Imaging data, especially by conventional radiographs, are
considered the ‘gold standard’ tool for assessing disease
modification. However, these data are not yet available.
Moreover, with regard to radiological evaluation, there are
two important limitations. First, radiographic progression is
typically slow in AS, often necessitating an interval of at least
2 years between successive images to permit the detection
of a meaningful difference. Second, a comparison with
placebo over this period is not realistic, given the impressive
short-term clinical results, thus necessitating the use of
historical cohorts as a comparison. To overcome these
limitations, new imaging modalities such as magnetic
resonance imaging have been proposed; however, the
question remains whether magnetic resonance imaging
provides information on the destruction or repair of the
structural tissue rather than on the inflammatory process
occurring in the bone tissue and at the site of the enthesis.
Whereas clinical measurements might be relatively insensitive
for assessing structure-modifying capacities, and radiological
evaluations require longer-term follow-up, it is tempting to
hypothesize that the evaluation of biological immuno-
modulation by TNF-α blockade might provide additional
evidence for a disease-modifying effect in SpA. In this context
it should be seen not only as inhibition of bone and cartilage
destruction but more broadly as modulation of tissue
histology rather than just downregulation of inflammation. The
major drawback of histopathological evaluations in AS is that
most tissues targeted by the disease are not easily
accessible for biopsy sampling (uvea, axial skeleton,
sacroiliac joints, and enthesis). With regard to peripheral joint
inflammation, the feasibility of repeated synovial biopsy
sampling has led to several studies of SpA [10,11]. As well
as a significant reduction in the number of macrophages and
polymorphonuclear cells in the sublining layer and an
impaired expression of vascular cell adhesion molecule-1,
suggesting that infliximab acts on synovitis in SpA by
reducing the influx of inflammatory cells, there was a123
decrease in the hypervascularity typical of SpA and a
reduction of the synovial lining hyperplasia, indicating that
infliximab also modulates the structural synovial charac-
teristics of the disease. In another study [12], synovial matrix
metalloproteinases were significantly downregulated by
treatment with infliximab. Because matrix metalloproteinases
are involved in neovascularization, matrix degradation, and
cartilage and bone destruction, the observed effect might
support the concept that TNF-α blockade could influence
structural damage in the long term. These and other
mechanisms of tissue remodelling might become unique
short-term biomarkers that could predict the long-term effect
of new treatment modalities on the structural damage in SpA.
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